Literature DB >> 3063684

CNS involvement in acute organophosphate poisoning: specific pattern of toxicity, clinical correlates and antidotal treatment.

Y Finkelstein1, U Taitelman, A Biegon.   

Abstract

The present review was designed to integrate both experimental and clinical data and to focus on the problems of management of severe cases of acute organophosphate poisoning, which always show CNS involvement. AChE activity, in discrete regions of the human brain, was studied by quantitative histochemistry of 40 mu thick sections. The regional effects of AChE inhibition by organophosphates was examined in a comparative study of the brains of two victims and two control brains, matched for age and sex. The pattern of AChE inhibition was regionally selective. The most significant decreases were observed in the neocerebellum, thalamic nuclei and the cortex. This specific distribution of AChE inhibition may be correlated with some of the clinical characteristics of acute organophosphate poisoning. The diagnostic value of blood AChE levels was examined in a personal series of 53 patients, who needed artificial ventilation, intensive care monitoring and antidotal treatment. The effects and side-effects of the antidotal treatment were reassessed. Recommended regimen of therapy was outlined, based upon experience in this series and in recent animal studies. The logical therapy would be and almost always in the co-administration of an anticholinergic drug (usually atropine) and an AChE reactivator (oximes) in order to rapidly obtain the most beneficial effect in the critically ill patient. Seizures that do not respond to the specific antidotal therapy, should be treated with I.V. benzodiazepines. Artificial respiration and supportive measures are essential for patient' survival. They enable the patient to gain the necessary time for sufficient recovery of AChE activity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3063684     DOI: 10.1007/bf02337161

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN: 0392-0461


  41 in total

1.  The effects of sarin and atropine on the respiratory center and neuromuscular junctions of the rat.

Authors:  W C STEWART
Journal:  Can J Biochem Physiol       Date:  1959-05

2.  The pathology of experimental cholinesterase-inhibitor poisoning.

Authors:  B HOLMSTEDT; L KROOK; J R ROONEY
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1957

3.  The failure of respiration in death by anticholinesterase poisoning.

Authors:  C A DE CANDOLE; W W DOUGLAS; C L EVANS; R HOLMES; K E SPENCER; R W TORRANCE; K M WILSON
Journal:  Br J Pharmacol Chemother       Date:  1953-12

4.  Acetylcholine content and cholinesterase activity in the ponto-medullary region of brain in rats treated with armin and obidoxime.

Authors:  B Vasíc; M P Milosević; M R Terzić
Journal:  Biochem Pharmacol       Date:  1977-04-01       Impact factor: 5.858

5.  The reactivatibility of cholinesterase inhibited by VX and sarin in man.

Authors:  F R Sidell; W A Groff
Journal:  Toxicol Appl Pharmacol       Date:  1974-02       Impact factor: 4.219

6.  [Therapeutic effectiveness of atropine and dipyroxime].

Authors:  R Kh Khaitov; T B Baĭmuradov; U S Kadyrov
Journal:  Veterinariia       Date:  1972-11

7.  VII. Toxicology and physiology. EEG, psychological, and neurological alterations in humans with organophosphorus exposure.

Authors:  D R Metcalf; J H Holmes
Journal:  Ann N Y Acad Sci       Date:  1969       Impact factor: 5.691

8.  An inexpensive microcomputer-based image-analysis system: novel applications to quantitative autoradiography.

Authors:  A Isseroff; D Lancet
Journal:  J Neurosci Methods       Date:  1985-02       Impact factor: 2.390

9.  Organophosphorus poisoning.

Authors:  J A Vale; G W Scott
Journal:  Guys Hosp Rep       Date:  1974

10.  Molecular forms and solubility of acetylcholinesterase during the embryonic development of rat and human brain.

Authors:  F Muller; Y Dumez; J Massoulié
Journal:  Brain Res       Date:  1985-04-08       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.